Abstract
Background
In the last decade, magnetic resonance imaging (MRI) has grown dramatically. At the same time, a growing number of patients receive cardiovascular implantable electronic devices (pacemaker, implantable-cardioverter defibrillators, bi-ventricular devices), a known contraindication to MRI. It has been estimated that a patient with a cardiovascular electronic device has a 50-75% lifetime requirement for MRI, which would usually be denied [1] . A position paper from the European Heart Rhythm Association and the Working Group on Cardiovascular Magnetic Resonance of the European Society of Cardiology [1] and a scientific statement from the American Heart Association [2] on MRI in individuals with cardiovascular implantable electronic devices have been published. Recently, an MRI-conditional dual chamber pacemaker has become available and represents an important step forward to overcome one of the major limitations of MRI.
Case presentation
A 53 year old woman presented with fatigue in complete heart block. Transthoracic echocardiography was normal. Six years previously, neuro-sarcoidosis presenting with diplopia and hydrocephalus had been confirmed by meningeal biopsy, and an MRI-conditional programmable Ventriculo-Peritoneal shunt (PS Medical Strata ® valve, Medtronic) had been inserted. In view of her ongoing need for neuro-imaging, MRI-conditional dual chamber pacemaker and leads (Advisa DR MRI™ SureScan™ with 5086 leads, Medtronic, Figure 1 ) were implanted. Subsequently, in September 2010, cardiac and brain MRI were requested to guide immunosupression. Following appropriate protocols for both MRI conditional devices, interleaved pre and post contrast cardiac, brain, and orbit MRI were performed in one session at 1.5T. Prior to scanning, the pacemaker was interrogated, lead integrity checked and device switched to DOO mode at 60 bpm at 5V@1ms (from 2V@0.4ms). Post scanning, all pacemaker parameters were unaffected, and normal operation was reprogrammed. Similarly, the programmable VP shunt, whose settings alter with scanning, was reset. 
Brain MRI showed susceptibility artefact associated with the shunt (Figure 2 ), but otherwise stable intracranial disease with scattered white matter lesions and persistent dural enhancement. Cardiac MRI showed normal LV size and systolic function with no regional wall motion abnormalities. Metallic lead artefact was minimised by switching standard SSFP cine sequence ( Figure 3 and additional file 1) to spoiled gradient echo -but was not considered necessary. T2-weighted images showed basal antero-septal oedema and there was extensive sub-epicardial, sometimes transmural, basal late gadolinium enhancement (Figure 4) . Overall the scans demonstrated stable neurological disease, but confirmed cardiac sarcoid, with oedema suggesting active disease.
Conclusions
The advent of MRI-conditional devices overcomes an important limitation in disease management. Here, a multidisciplinary team approach and the use and management of two concurrent MR conditional devices [3] permitted ongoing, comprehensive assessment of multisystem sarcoidosis [4, 5] . Ironically, cardiovascular MRI detected occult cardiac disease that suggests the possible future requirement for an implantable-cardioverter defibrillator. As yet, such devices are not MRI conditional. Fortunately, she has no other high risk features [6] and her device has not detected any ventricular arrhythmia. Our case illustrates why sarcoid patients who develop bradyarrhythmias should ideally have an MRI-conditional pacing system.
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Oedema
LGE Figure 4 Cardiac MRI with T2-weighted STIR images (left panel) showing oedema (arrow) and (middle and right panels) extensive patchy late gadolinium enhancement typical of sarcoid.
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